Insulin secretion is controlled by a complex set of factors that include not only glucose but amino acids, catecholamines, and intestinal hormones. We report that a novel glucagon-like peptide, co-encoded with glucagon in the glucagon gene is a potent insulinotropic factor. The glucagon gene encodes a proglucagon that contains in its sequence glucagon and additional glucagon-like peptides (GLPs). These GLPs are liberated from proglucagon in both the pancreas and intestines. GLP-I exists in at least two forms: 37 amino acids GLP-I(1-37), and 31 amino acids, GLP-I(7-37). We studied the effects of synthetic GLP-Is on insulin secretion in the isolated perfused rat pancreas. In the presence of 6.6 mM glucose, GLP-I(7-37) is a potent stimulator of insulin secretion at concentrations as low as 5 X 10(-11) M (3- to 10-fold increases over basal). GLP-I(1-37) had no effect on insulin secretion even at concentrations as high as 5 X 10(-7) M. The earlier demonstration of specific liberation of GLP-I(7-37) in the intestine and pancreas, and the magnitude of the insulinotropic effect at such low concentrations, suggest that GLP-I(7-37) participates in the physiological regulation of insulin secretion. Images
Svetlana Mojsov, Gordon C. Weir, Joel F. Habener
Year: | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1985 | 1964 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Citations: | 9 | 23 | 12 | 13 | 21 | 12 | 24 | 25 | 18 | 31 | 19 | 35 | 24 | 15 | 130 | 39 | 17 | 23 | 16 | 18 | 14 | 13 | 12 | 9 | 11 | 16 | 11 | 13 | 10 | 18 | 17 | 12 | 13 | 18 | 11 | 12 | 11 | 10 | 5 | 1 | 1 | 762 |
Title and authors | Publication | Year |
---|---|---|
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
MJ Theodorakis, O Carlson, S Michopoulos, ME Doyle, M Juhaszova, K Petraki, JM Egan |
American journal of physiology. Endocrinology and metabolism | 2005 |
Prevalence, predisposition and prevention of type II diabetes
D Cheng |
Nutrition & Metabolism | 2005 |
A Possible Role of GLP-1 in the Pathophysiology of Early Dumping Syndrome
H Yamamoto, T Mori, H Tsuchihashi, H Akabori, H Naito, T Tani |
Digestive Diseases and Sciences | 2005 |
Significance of Prohormone Convertase 2, PC2, Mediated Initial Cleavage at the Proglucagon Interdomain Site, Lys70-Arg71, to Generate Glucagon
A Dey, GM Lipkind, Y Rouillé, C Norrbom, J Stein, C Zhang, R Carroll, DF Steiner |
Endocrinology | 2005 |
Alpha cell function in health and disease: influence of glucagon-like peptide-1
BE Dunning, JE Foley, B Ahrén |
Diabetologia | 2005 |
The incretins: a link between nutrients and well-being
R Burcelin |
British Journal of Nutrition | 2005 |
The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management
OA Roges, M Baron, A Philis-Tsimikas |
Expert Opinion on Investigational Drugs | 2005 |
Glucagon-like peptide 1(GLP-1) in biology and pathology
JJ Meier, MA Nauck |
Diabetes/Metabolism Research and Reviews | 2005 |
Exenatide: a novel treatment of Type 2 diabetes
B Ahren |
Therapy | 2005 |
Gastrointestinal Physiology
WC Orr |
Principles and Practice of Sleep Medicine | 2005 |
The [pre-] history of the incretin concept
W Creutzfeldt |
Regulatory Peptides | 2005 |
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice
T Hansotia, DJ Drucker |
Regulatory Peptides | 2005 |
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
MA Nauck, JJ Meier |
Regulatory Peptides | 2005 |
Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome
PE Wiedeman, JM Trevillyan |
Drug Discovery Today: Therapeutic Strategies | 2005 |